Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Tysabri – Therapeutic Monoclonal Antibody (Mab) for the Treatment of Multiple Sclerosis

Drug (brand / generic)

Tysabri (natalizumab)

Company / Licensee

Elan Pharmaceuticals/ Biogen

Therapy Class

Selective Adhesion-Molecule Inhibitor

Product Description

Alpha-4 antagonist

Current Indication

Treatment of multiple sclerosis

Market Sector

CNS

Development Status

Launched US end 2004; recalled February 2005; reintroduced July 2006. Approved Europe
Expand

Free download worth over $5000
Download our 2019 Technology, Media and Telecoms Predictions Report

Worth up to $5,850

In this report, we look at the 30 big tech themes for 2019, identifying winners and losers for each theme. This report will impact all industries helping:

  • CEOs/Senior Staff: in all industries understand the disruptive threats to their competitive landscape
  • Investors: Helps fund managers focus their time on the most interesting investment opportunities in global TM

Go Top